Mariana Michelle Ramírez-Mejía

Mariana Michelle Ramírez-Mejía

Auto-generated profile, based on publicly available information

Mariana Michelle Ramírez-Mejía

Liver Research Unit, Medica Sur Clinic and Foundation, Mexico City 14050, Mexico; Plan of Combined Studies in Medicine (PECEM-MD/PhD), Faculty of Medicine, National Autonomous University of Mexico, Mexico City 04360, Mexico

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2023 in Hepatology International
Verified
Journal Article
Closed access
PDF file
MRMariana Michelle Ramírez-Mejía
Mariana Michelle Ramírez-Mejía
CGCarlos Jimenez Gutierrez
Carlos Jimenez Gutierrez
MEMohammed Eslam
Mohammed Eslam
JGJacob George
Jacob George
Nahum Mendez-SanchezNahum Mendez-Sanchez
Nahum Mendez-Sanchez

21 October 2024 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
MRMariana M. Ramírez-Mejía
Mariana M. Ramírez-Mejía
SCStephany Mercedes Castillo-Castañeda
Stephany Mercedes Castillo-Castañeda
SPShreya C. Pal
Shreya C. Pal
XQXingshun Qi
Xingshun Qi
Nahum Mendez-SanchezNahum Mendez-Sanchez
Nahum Mendez-Sanchez
Bilirubin, the primary breakdown product of hemoproteins, particularly hemoglobin, plays a key role in the diagnosis, prognosis, and monitoring of liver diseases. In acute liver diseases, such as acute liver failure, drug-induced liver injury, and viral hepatitis, bilirubin serves as a biomarker reflecting the extent of hepatocyte loss and liver damage. Chronic liver diseases, including alcohol-related liver disease, chronic hepatitis C virus infection, metabolic dysfunction-associated fatty liver disease, and autoimmune liver diseases, are marked by persistent liver injury and inflammation. Bilirubin levels in chronic liver diseases provide insight into liver function, disease severity, and prognosis. As a versatile biomarker, bilirubin offers valuable information on the pathophysiology of liver diseases and aids in guiding clinical decision-making regarding the treatment of liver diseases and their complications. This review aimed to explore the multifunctional role of bilirubin in liver diseases by analyzing its biological functions beyond its role as a biomarker of liver damage.

19 April 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
Nahum Mendez-SanchezNahum Mendez-Sanchez
Nahum Mendez-Sanchez
Carlos Esteban Coronel-CastilloCarlos Esteban Coronel-Castillo
Carlos Esteban Coronel-Castillo
MRMariana Michelle Ramírez-Mejía
Mariana Michelle Ramírez-Mejía
Chronic hepatitis C virus infection is an important cause of liver cirrhosis, hepatocellular carcinoma and death. Furthermore, it is estimated that about 40–70% of patients develop non-hepatic alterations in the course of chronic infection. Such manifestations can be immune-related conditions, lymphoproliferative disorders and metabolic alterations with serious adverse events in the short and long term. The introduction of new Direct-Acting Antivirals has shown promising results, with current evidence indicating an improvement and remission of these conditions after a sustained virological response.

26 October 2023 in Current Hepatology Reports
Verified
Journal Article
Closed access
PDF file
MRMariana M. Ramírez-Mejía
Mariana M. Ramírez-Mejía
Nahum Mendez-SanchezNahum Mendez-Sanchez
Nahum Mendez-Sanchez

3 November 2025 in Archives of Medical Research
Verified
Journal Article
Closed access
MRMariana M. Ramírez-Mejía
Mariana M. Ramírez-Mejía
GPGuadalupe Ponciano-Rodríguez
Guadalupe Ponciano-Rodríguez
Nahum Mendez-SanchezNahum Mendez-Sanchez
Nahum Mendez-Sanchez

Verified
Journal Article
Open access
PDF file
SCStephany Mercedes Castillo-Castañeda
Stephany Mercedes Castillo-Castañeda
JCJaqueline Cordova-Gallardo
Jaqueline Cordova-Gallardo
LRLiliana Rivera-Espinosa
Liliana Rivera-Espinosa
Juan Luis Chávez PachecoJuan Luis Chávez Pacheco
Juan Luis Chávez Pacheco
MRMariana M. Ramírez-Mejía
Mariana M. Ramírez-Mejía
Nahum Mendez-SanchezNahum Mendez-Sanchez
Nahum Mendez-Sanchez
Bilirubin plays a key role in early diagnosis, prognosis, and prevention of liver diseases. Unconjugated bilirubin (UCB) requires conversion to a water-soluble form through liver glucuronidation, producing monoglucuronide (BMG) or diglucuronide bilirubin (BDG) for bile excretion. This study aimed to assess the roles of bilirubin’s molecular species—UCB, BMG, and BDG—in diagnosing and understanding the pathogenesis of liver cirrhosis in patients with acute-on-chronic liver failure (ACLF), compensated liver cirrhosis (LC) patients, and healthy individuals. The study included patients with ACLF and compensated LC of diverse etiologies, along with healthy controls. We collected laboratory and clinical data to determine the severity and assess mortality. We extracted bilirubin from serum samples to measure UCB, BMG, and BDG using liquid chromatography–mass spectrometry (LC-MS). The quantification of bilirubin was performed by monitoring the mass charge (m/z) ratio. Of the 74 patients assessed, 45 had ACLF, 11 had LC, and 18 were healthy individuals. Among ACLF patients, the levels of molecular species of bilirubin were UCB 19.69 μmol/L, BMG 47.71 μmol/L, and BDG 2.120 μmol/L. For compensated cirrhosis patients, the levels were UCB 11.29 μmol/L, BMG 1.49 μmol/L, and BDG 0.055 μmol/L, and in healthy individuals, the levels were UCB 6.42 μmol/L, BMG 0.52 μmol/L, and BDG 0.028 μmol/L. The study revealed marked elevations in the bilirubin species in individuals with ACLF compared to those with compensated cirrhosis and healthy controls, underscoring the progression of liver dysfunction. The correlation of BMG and BDG levels with commonly used inflammatory markers suggests a relationship between bilirubin metabolism and systemic inflammation in ACLF.